reports
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Thera...
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc. Separately today, Akebia announced that its stockholders voted to approve the share issuance proposal relating to the merger with Keryx at a special meeting of Akebia stockholders. “The...
Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote...
Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics BOSTON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends Keryx stockholders vote “FOR” the proposals relating to the proposed merger with Akebia Therapeutics, Inc. (Nasdaq: AKBA) at the Special Meeting of Keryx stockholders to be held...
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR...
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics Leading proxy advisory firm recognizes the strategic and financial merits of the merger BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommends Keryx stockholders vote “FOR” the merger and the proposals relating to the propos...
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Result...
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017Approximately 47,500 Auryxia Prescriptions were written in the third quarter of 2018, nearly double the number reported in the third quarter of 2017Merger with Akebia Therapeutics on track to close by year end, subject to stockholder approval and the satisfaction of other closing conditions BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- K...
Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Resul...
Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018 BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018 at approximately 4:30 p.m. ET. Keryx will not be conducting a conference call in conjunction with its third quarter 2018 earnings release given its pending merger with Akebia Therapeutics, Inc. ...
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy St...
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders to vote “FOR” the Merger Proposals Keryx Special Meeting of Stockholders Scheduled for December 11, 2018 BOSTON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that it and Akebia Therapeutics, Inc. (NASDAQ: AKBA) have filed definitive proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with t...
KERYX BIOPH.INCO. reduces its risk exposure and slightly improves to N...
The independent financial analyst theScreener just allocated a lower risk rating to KERYX BIOPH.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 26, 2018, the closing price was USD 3.01 and its expec...
Keryx Biopharmaceuticals Announces Participation in an Upcoming Inves...
Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will participate in the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 in New York. At the conference, Keryx will be participating in a 25 minute panel discussion titled Renal Anemia on Tuesday, October 2, 2018 at 3:30 p.m. Eastern time at the Sofitel New York in New Yor...
Keryx Biopharmaceuticals Announces Second Quarter 2018Â Financial Resu...
Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results Second quarter 2018 total revenues of $25.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $24.1 million; a 71 percent increase compared to the second quarter of 2017Approximately 42,500 Auryxia Prescriptions were written in the second quarter of 2018, double the number reported in the second quarter of 2017Conference call today at 8:00 a.m. BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative me...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 201...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018 BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its second quarter 2018 financial results and provide a business update. To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (internation...
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Pa...
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced participating in an upcoming panel in New York City. The JMP Securities Life Sciences Conference on Thursday, June 21st at 11:00 a.m. Eastern time: Keryx will be participating in a 50 minute panel discussion titled Renal Disease: Recent Advanceme...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
KERYX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Lo...
NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until October 3, 2016 to file lead plaintiff applications in a securities class action lawsuit against Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX). Investor losses must relate to purchases of the Company’s common stock between February 25, 2016, and August 1, 2016. This action is pending in the United States District Court f...
October 3rd Deadline Alert: GPM Reminds Investors of the Upcoming Dead...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 3, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Keryx Pharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX) securities in the newly expanded Class Period of September 2, 2013 and August 1, 2016, inclusive (the “Class Period”). Keryx investors have October 3, 2016 to file a lead plaintiff motion. The complaint filed in ...
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Keryx B...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) between February 25, 2016 and August 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/keryx-biopharmaceuticals-inc or contact Joseph E. Lev...
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx B...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you, or did you, own shares of Keryx Biopharmaceuticals, Inc. (NASDAQ CM: KERX)? Did you purchase your shares between February 25, 2016 and August 1, 2016, inclusive? Did you lose money in your investment? Rigrodsky & Long, P.A. reminds shareholders of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQ CM: KERX) of an upcoming deadline involving a securities fraud class action ...
KERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Invest...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) securities February 25, 2016 and August 1, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/keryx-biopharmaceuticals. There is no cost or obligation to you. According to the complaint, throughout the Class Period, Defendants made materially false and/...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.